GLP-1 Users Are Spending Way Less on Groceries and Fast Food, According to a New Study
Recent research out of Cornell University showed that GLP-1 users' grocery bills have been reduced by as much as 8.6% — with ...
Hollywood’s slimming secret: The Ozempic trend – Here’s what experts really think
The rise of ultra-thin bodies in Hollywood, fueled by the popularity of weight loss medications, marks a dramatic shift in ...
Jim Cramer Says J. M. Smucker (SJM) Can’t ‘Overrun Sentiment’ Amid Weight Loss Drugs Threat
Jim Cramer in a latest program mentioned an analyst downgrade on The J. M. Smucker Company (NYSE:SJM) and reiterated that he ...
Futurism8h
Huge Study Finds Constellation of Health Benefits for Ozempic Beyond Weight Loss
In a ginormous new study, researchers have begun mapping the manifold health benefits of drugs like Ozempic and Wegovy beyond ...
oprahdaily11h
Oprah Reflects on Weight and Shame
"Today, we have GLP-1s designed specifically for weight loss and there is greater public awareness around the benefits of these medications." ...
devdiscourse11h
Breakthrough in Muscle Preservation: BCL6 Protein's Role Unveiled
New research highlights the potential of the protein BCL6 in preserving muscle mass, especially when used with popular weight ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.
GLP-1 drugs like Ozempic may have health benefits, but they come with risks
With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...
MM&M2d
Novo Nordisk’s amycretin cuts weight by 22% in early obesity trial
The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.
Novo Nordisk stock surges 7% after Ozempic maker’s latest weight loss drug shows promise
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
Sweeping New Study Confirms Serious Ozempic Side Effects: What A Doctor Wants You To Know
Most people know that GLP-1 receptor agonist medications like Ozempic and Wegovy can cause relatively minor side effects like ...